Workflow
EGFR - mutated non - small cell lung cancer (NSCLC) treatment
icon
Search documents
Black Diamond Therapeutics: A Potential First-Line In NSCLC Trading At Cash
Seeking Alphaยท 2025-08-25 15:13
Company Overview - Black Diamond Therapeutics (BDTX) is a clinical stage biotechnology firm focused on developing treatments for EGFR-mutated non-small cell lung cancer (NSCLC) [1] Product Development - The main candidate of BDTX is BDTX-1535, also known as Silvertinib, which is currently being investigated in both first line and advanced lines of treatment for NSCLC [1]